{"id":"NCT02898077","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer","officialTitle":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-02","primaryCompletion":"2020-06-30","completion":"2021-04-12","firstPosted":"2016-09-13","resultsPosted":"2021-08-03","lastUpdate":"2022-06-14"},"enrollment":440,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Junction Adenocarcinoma","Gastric Adenocarcinoma"],"interventions":[{"type":"DRUG","name":"Ramucirumab","otherNames":["LY3009806"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel","type":"EXPERIMENTAL"},{"label":"Placebo + 80 mg/m² Paclitaxel","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months)","effectByArm":[{"arm":"8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel","deltaMin":4.14,"sd":null},{"arm":"Placebo + 80 mg/m² Paclitaxel","deltaMin":3.15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0184"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":32,"countries":["China","Malaysia","Philippines","Thailand"]},"refs":{"pmids":["34626550"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":100,"n":293},"commonTop":["White blood cell count decreased","Neutrophil count decreased","Anaemia","Alopecia","Aspartate aminotransferase increased"]}}